Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 11, 2017, Pages 814-823

  Lawitz, Eric ^a   Buti, Maria ^b   Vierling, John M ^c   Almasio, Piero L ^d   Bruno, Savino ^e   Ruane, Peter J ^f   Hassanein, Tarek I ^g   Muellhaupt, Beat ^h   Pearlman, Brian ^i,j   Jancoriene, Ligita ^k   Gao, Wei ^l   Huang, Hsueh Cheng ^l   Shepherd, Aimee ^l   Tannenbaum, Brynne ^l   Fernsler, Doreen ^l   Li, Jerry J ^l   Grandhi, Anjana ^l   Liu, Hong ^l   Su, Feng Hsiu ^l   Wan, Shuyan ^l   Dutko, Frank J ^l   Nguyen, Bach Yen T ^l   Wahl, Janice ^l   Robertson, Michael N ^l   Barr, Eliav ^l   Yeh, Wendy W ^l   Plank, Rebeca M ^l   Butterton, Joan R ^l   Yoshida, Eric M ^m   more..

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PALERMO   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f Ruane Medical and Liver Health Institute   (United States)

^g Southern California Liver Centers   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ ATLANTA MEDICAL CENTER   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k VILNIUS UNIVERSITY   (Lithuania)

^l MERCK RESEARCH LABORATORIES   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRAZOPREVIR; RIBAVIRIN; RUZASVIR; UPRIFOSBUVIR; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; MK-5172; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; CLINICAL OUTCOME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL; PHYLOGENY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEPSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY; SUSTAINED VIROLOGIC RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRROLIDINES; QUINOXALINES; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; THIAZOLES;

EID: 85032295255     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30163-2     Document Type: Article

References (20)

1. Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
2. Denniston, MM, Jiles, RB, Drobeniuc, J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160 (2014), 293–300.
3. Blach, S, Zeuzem, S, Manns, M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
4. US Centers for Disease Control and Prevention. Viral hepatitis surveillance—United States. http://www.cdc.gov/hepatitis/hcv/statisticshcv.htm, 2014 (accessed Jan 16, 2017).
5. Chhatwal, J, Wang, XJ, Ayer, T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 64 (2016), 1442–1450.
6. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
7. Arends, JE, Kracht, PAM, Hoepelman, AIM, European Study Group for Viral Hepatitis. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 22 (2016), 846–852.
8. Coburn, CA, Meinke, PT, Chang, W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 8 (2013), 1930–1940.
9. Tong, L, Yu, W, Chen, L, et al. Discovery of ruzasvir (MK-8408): a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms. J Med Chem 60 (2017), 290–306.
10. Gane, EJ, Pianko, S, Roberts, SK, et al. Phase 2, randomized, open-label clinical trials of the efficacy and safety of grazoprevir and MK-3682 (NS5B polymerase inhibitor) with either elbasvir or MK-8408 (NS5A inhibitor) in patients with chronic HCV GT1, 2 or 3 infection (part A of C-CREST-1 & 2). Hepatology, 62, 2015, 1389A-A.
11. Gane, E, Pianko, S, Roberts, S, Thompson, A, et al. Phase 2, randomized, open-label clinical trials of the efficacy and safety of grazoprevir and MK-3682 (NS5B polymerase inhibitor) with either elbasvir or MK-8408 (NS5A inhibitor) in patients with chronic HCV GT1, 2 or 3 infection (part A of C-CREST-1 & 2). HEP DART—Frontiers in Drug Development for Viral Hepatitis; Dec 6–10, 2015; Wailea, HI, USA. http://www.natap.org/2015/hepDART/hepDART_06.htm (accessed June 2, 2017).
12. Clopper, CJ, Pearson, ES, The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26 (1934), 404–413.
13. Gane, EJ, Pianko, S, Roberts, SK, et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30159-0.
14. US Food and Drug Administration. Full prescribing information for ZEPATIER (elbasvir and grazoprevir) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf, 2017 (accessed May 24, 2017).
15. Foster, GR, Afdhal, N, Roberts, SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
16. AASLD, IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/ (accessed March 20, 2017).
17. Zeuzem, S, Feld, JJ, Wang, S, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection. Hepatology 63 (2016), 132A–133A.
18. Asselah, T, Hezode, C, Zadeikis, N, et al. ENDURANCE-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology, 63, 2016, 63A-A.
19. Kowdley, KV, Colombo, M, Zadeikis, N, et al. ENDURANCE-2: safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study. Hepatology, 63, 2016, 39A-A.
20. Wyles, DL, Poordad, F, Wang, S, et al. SURVEYOR-II, part 3: efficacy and safety of ABT-493/ABT-530 in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. Hepatology 63 (2016), 62A–63A.